Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Laboratory Corporation of America Holdings    LH

LABORATORY CORPORATION OF AMERICA HOLDINGS

(LH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/15/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
223.71(c) 225.74(c) 229.91(c) 228.45(c) 228.9(c) Last
628 157 925 999 811 972 635 001 612 334 Volume
+1.59% +0.91% +1.85% -0.64% +0.20% Change
More quotes
Financials (USD)
Sales 2020 13 462 M - -
Net income 2020 1 631 M - -
Net Debt 2020 4 754 M - -
P/E ratio 2020 13,7x
Yield 2020 -
Sales 2021 13 992 M - -
Net income 2021 1 640 M - -
Net Debt 2021 3 719 M - -
P/E ratio 2021 13,6x
Yield 2021 -
Capitalization 22 295 M 22 295 M -
EV / Sales 2020 2,01x
EV / Sales 2021 1,86x
Nbr of Employees 65 000
Free-Float 99,4%
More Financials
Company
Laboratory Corporation of America Holdings is the No. 2 clinical laboratory in the United States. Net sales (including intragroup) break down by activity as follows: - supply of testing services (59.5%): routine testing, patient diagnosis, disease monitoring and treatment, and other services; - supply of genomic and esoteric testing services (40.5%). Net sales are distributed geographically as follows : the... 
More about the company
Notations Surperformance© of Laboratory Corporation of America Holdings
Trading Rating : Investor Rating :
More Ratings
All news about LABORATORY CORPORATION OF AMERICA HOLDINGS
01/20LABORATORY OF AMERICA : Labcorp Appoints Dr. Deborah Ann Sesok-Pizzini as Chief ..
AQ
01/19LABCORP : Appoints Dr. Deborah Ann Sesok-Pizzini as Chief Medical Officer, Labco..
BU
01/11LABORATORY OF AMERICA : Labcorp to Announce Fourth Quarter and Full Year 2020 Fi..
AQ
01/08LABCORP : to Announce Fourth Quarter and Full Year 2020 Financial Results on Feb..
BU
01/07LABORATORY OF AMERICA : Gets CDC Contract for Genomic Sequencing of SARS-CoV-2 S..
MT
01/07LABCORP : Awarded CDC Contract to Study Variants of COVID-19 Virus and Improve P..
BU
01/06LABORATORY OF AMERICA : Brian Caveney, Chief Medical Officer and President of La..
BU
01/05LABORATORY OF AMERICA : View HTML
PU
01/05LABCORP : Is Scheduled to Virtually Participate at the 39th Annual J.P. Morgan H..
BU
2020LABORATORY OF AMERICA : Walgreens and Labcorp Make Pixel by Labcorp™ At-Ho..
BU
2020LABORATORY OF AMERICA : Covance, LabCorp's Drug Development Business, Acclaimed ..
AQ
2020ETF PREVIEW : ETFs, Futures Mixed as Latest Stimulus Proposal Rejected; Congress..
MT
2020LabCorp Secures FDA Emergency Use Authorization for COVID-19 Test Home Collec..
MT
2020LABCORP : Receives FDA Authorization to Make At-Home COVID-19 Collection Kits Av..
BU
2020ROCHE : Gets FDA Emergency Use OK for Test to Measure Level of SARS-CoV-2 Antibo..
DJ
More news
News in other languages on LABORATORY CORPORATION OF AMERICA HOLDINGS
2020ROCHE : erhält FDA-Notfallzulassung für Sars-CoV-2-Antikörpertest
2020LABORATORY CORPORATION OF AMERICA HO : publication des résultats trimestriels
2020LABORATORY CORPORATION OF AMERICA HO : Veröffentlichung des Quartalsergebnisses
2020GENFIT : signe un contrat exclusif de licence avec LabCorp pour un test de la NA..
2020LABORATORY CORPORATION OF AMERICA HO : publication des résultats semestriels
More news
Analyst Recommendations on LABORATORY CORPORATION OF AMERICA HOLDINGS
More recommendations
Stock Trading Strategies
LABORATORY CORPORATION OF AMERICA HOLDINGS - 01/06
Close to a key resistance level
BUY
More Stock Trading Analysis
Chart LABORATORY CORPORATION OF AMERICA HOLDINGS
Duration : Period :
Laboratory Corporation of America Holdings Technical Analysis Chart | LH | US50540R4092 | MarketScreener
Technical analysis trends LABORATORY CORPORATION OF AMERICA HOLDINGS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Average target price 247,27 $
Last Close Price 228,90 $
Spread / Highest target 24,5%
Spread / Average Target 8,02%
Spread / Lowest Target -8,69%
EPS Revisions
Managers and Directors
NameTitle
Adam H. Schechter President, Chief Executive Officer & Director
Glenn Andrew Eisenberg Chief Financial Officer, Treasurer & Executive VP
Lance V. Berberian Chief Information Officer & Senior Vice President
Brian J. Caveney Chief Medical Officer, EVP & President-Diagnostics
Stephen M. Anderson Chief Scientific Officer-Covance & Senior VP